Federico Hinestrosa

机构：University of Central Florida, Orlando Immunology Center, Florida College · ORCID：0000-0003-3687-8168

发表论文 49 篇 · 总被引 2567 次 · h-index 17

代表论文

• Real-world efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide in older people living with HIV (2021 · Medicine · 被引 51)
• Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trial (2024 · The Lancet HIV · 被引 31)
• Virologic outcomes of switching to dolutegravir functional mono- or dual therapy with a non-cytosine nucleoside analog: a retrospective study of treatment-experienced, patients living with HIV (2021 · AIDS Research and Therapy · 被引 21)
• Efficacy, Safety, and Tolerability of Switching From Bictegravir/Emtricitabine/Tenofovir Alafenamide to Dolutegravir/Lamivudine Among Adults With Virologically Suppressed HIV: The DYAD Study (2024 · Open Forum Infectious Diseases · 被引 19)
• Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial (2026 · The Lancet · 被引 14)
• Doravirine/Islatravir (100/0.75 mg) Once-Daily Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial HIV-1 Treatment: 48-Week Results From a Phase 3, Randomized, Controlled, Double-Blind, Noninferiority Trial (2025 · Clinical Infectious Diseases · 被引 14)